Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

ASH 2019 | Should we act therapeutically on MRD positivity in AML?

Christoph Röllig • 7 Dec 2019
ASH 2019
Acute Myeloid Leukemia Leukemia Azacitidine

Christoph Röllig, MD, MSc, University Hospital Carl Gustav Carus, Dresden, Germany, discusses the measurement of residual disease in acute myeloid leukemia (AML), and the question of whether we should act therapeutically on MRD positivity in AML. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.

More from Christoph Röllig

Venetoclax in combination with hypomethylating agents in adult patients with newly diagnosed CBF-AML 2:41
Venetoclax in combination with hypomethylating agents in adult patients with newly diagnosed CBF-AML
Christoph Röllig • 5 Dec 2025
Challenges associated with relapsed AML and the value of targeted agents 2:52
Challenges associated with relapsed AML and the value of targeted agents
Christoph Röllig • 3 Sep 2025
Insights into the VINCENT trial: venetoclax + azacitidine versus intensive chemotherapy in NPM1m AML 2:18
Insights into the VINCENT trial: venetoclax + azacitidine versus intensive chemotherapy in NPM1m AML
Christoph Röllig • 3 Sep 2025
Secondary-type mutations do not impact the favorable prognosis in NPM1-mutated AML 2:19
Secondary-type mutations do not impact the favorable prognosis in NPM1-mutated AML
Christoph Röllig • 11 Dec 2023

Related Videos

Real-world outcomes of olutasidenib in IDH1-mutated AML previously treated with venetoclax 2:14
Real-world outcomes of olutasidenib in IDH1-mutated AML previously treated with venetoclax
Jorge Cortes • 7 Dec 2025
Preliminary human data and clinical implications of asciminib administration during pregnancy in CML 5:08
Preliminary human data and clinical implications of asciminib administration during pregnancy in CML
Elisabetta Abruzzese • 5 Dec 2025
Patient-reported outcomes from ASC4FIRST study of asciminib in newly diagnosed CML 2:22
Patient-reported outcomes from ASC4FIRST study of asciminib in newly diagnosed CML
Jorge Cortes • 7 Dec 2025
MRD-guided treatment with ibrutinib and venetoclax in previously untreated CLL: analyses of FLAIR 7:15
MRD-guided treatment with ibrutinib and venetoclax in previously untreated CLL: analyses of FLAIR
Talha Munir • 16 Dec 2025
The content of VJHemOnc is intended for healthcare professionals